NCT05305105View on ClinicalTrials.gov

Effects of Psilocybin in Post-Treatment Lyme Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

October 26, 2024

Study Completion Date

April 7, 2025

Conditions
Post-Treatment Lyme DiseaseChronic Lyme DiseaseLyme Disease, Chronic
Interventions
DRUG

Psilocybin

Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit, Baltimore

All Listed Sponsors
collaborator

Steven & Alexandra Cohen Foundation

OTHER

collaborator

Usona Institute

OTHER

lead

Johns Hopkins University

OTHER